Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

The Lancet: Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

Co Authored by Cyril P Clarke, Vice President Translational Medicine and Jonathan H Goldman, Executive Vice President Strategic Programs and Alliance Management

Click here to view on The Lancet.com